Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DORZOLAMIDE HYDROCHLORIDE vs DARANIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.
Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.
Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma,Adjunctive therapy with beta-blockers in patients with open-angle glaucoma or ocular hypertension
Edema due to congestive heart failure,Drug-induced edema,Glaucoma (adjunctive therapy)
One drop of 2% solution in the affected eye(s) three times daily.
50 mg orally once or twice daily; maximum 100 mg/day.
Terminal elimination half-life is approximately 4 months for red blood cell carbonic anhydrase II binding; systemic half-life of free drug is about 3-4 hours.
Terminal elimination half-life: 2.5-3.5 hours (prolonged in renal impairment). Clinical context: Short half-life necessitates multiple daily dosing for sustained diuretic effect.
Dorzolamide is metabolized primarily by hepatic cytochrome P450 enzymes, specifically CYP2C9, to N-desethyl-dorzolamide. It forms N-acetylated metabolites as well as the N-desethyl metabolite. Minor renal elimination of unchanged drug occurs.
Not extensively metabolized; excreted unchanged in urine.
Renal: approximately 70% of a topically applied dose is excreted unchanged in urine over 120 hours; <2% fecal.
Renal: unchanged drug (approximately 50% of absorbed dose) and metabolites. Biliary/fecal: minimal.
Approximately 33% bound to plasma proteins, primarily albumin.
~90% bound, primarily to albumin.
Wide distribution: apparent Vd is approximately 0.53 L/kg; extensive binding to carbonic anhydrase in red blood cells and tissues.
0.2-0.3 L/kg. Clinical meaning: Confined primarily to extracellular fluid; low Vd indicates minimal tissue distribution.
Topical ophthalmic: systemic absorption is minimal (approximately 2-4% of administered dose reaches systemic circulation due to nasolacrimal drainage and ocular absorption).
Oral: 75-85% (tablet).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild to moderate impairment; use with caution.
GFR 10-50 m L/min: 50 mg every 12-24 hours; GFR <10 m L/min: 50 mg every 24-48 hours; not effective if GFR <10 m L/min.
No specific dose adjustment required based on Child-Pugh classification; however, use with caution in severe hepatic impairment due to potential for systemic accumulation.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: use not recommended.
Safety and efficacy not established in pediatric patients. No standard weight-based dosing guidelines available. Some sources recommend the same adult dose (one drop of 2% solution three times daily) for children aged ≥2 years; use with caution.
Not established; use not recommended in children.
No specific dose adjustment required, but elderly patients may be more susceptible to systemic effects; monitor for ocular irritation and electrolyte imbalance.
Start at 25 mg once daily; monitor renal function and electrolyte balance due to increased risk of adverse effects.
None
None.
Sulfonamide hypersensitivity: Dorzolamide is a sulfonamide derivative; cross-reactivity may occur. Discontinue if signs of serious hypersensitivity reactions develop.,Corneal edema and endothelial decompensation: Use with caution in patients with compromised corneas (e.g., low endothelial cell count).,Ocular effects: Transient blurred vision, burning, stinging, and superficial punctate keratitis may occur.,Potential for metabolic acidosis: Carbonic anhydrase inhibitors can cause metabolic acidosis; use with caution in patients with renal impairment or those on concomitant topiramate or acetazolamide.,Bacterial keratitis: Risk with contaminated multidose containers.
May cause drowsiness, confusion, or paresthesias,Monitor electrolytes and renal function,Can cause metabolic acidosis,Use caution in patients with hepatic impairment or cirrhosis
Hypersensitivity to dorzolamide hydrochloride or any component of the formulation,Severe renal impairment (creatinine clearance < 30 m L/min),Hyperchloremic acidosis
Hypersensitivity to dichlorphenamide or other sulfonamides,Severe renal or hepatic dysfunction,Hypokalemia,Hyponatremia,Metabolic acidosis,Adrenal insufficiency
None known. No dietary restrictions are required with topical dorzolamide use.
No specific food interactions reported. However, maintain adequate hydration to reduce risk of kidney stones. Avoid excessive salt intake if edema is present. Grapefruit juice is not known to interact.
Dorzolamide is a carbonic anhydrase inhibitor. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2.5 mg/kg/day (rabbit) and 20 mg/kg/day (rat). Low systemic absorption (≈4% of ocular dose) minimizes fetal exposure. FDA Pregnancy Category C. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. No specific trimester risks.
Pregnancy Category C. First trimester: Possible association with congenital malformations (limited human data; animal studies show fetal toxicity). Second/third trimester: Risk of electrolyte disturbances and acidosis in neonate; avoid use unless benefit outweighs risk.
It is not known whether dorzolamide is excreted in human milk. Systemic absorption is low (≈4%). Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. M/P ratio not available. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for dorzolamide and potential adverse effects on the breastfed child.
Contraindicated in breastfeeding. Excreted in breast milk; M/P ratio not established. Potential for serious adverse effects in infant (metabolic acidosis, electrolyte imbalance).
No dose adjustment is recommended. The systemic absorption of topical dorzolamide is low (≈4%) and pharmacokinetics are not expected to change significantly in pregnancy. Use the standard adult dose: one drop in the affected eye(s) three times daily.
No standard dose adjustments; increased renal clearance in pregnancy may lower drug levels, but empirical dose changes are not recommended due to risk of metabolic acidosis. Use lowest effective dose if unavoidable.
Dorzolamide is a topical carbonic anhydrase inhibitor used for elevated intraocular pressure. It can cause metabolic acidosis due to systemic absorption, especially in patients with renal impairment. Avoid use with oral carbonic anhydrase inhibitors to prevent additive systemic effects. Monitor for corneal edema in patients with compromised corneas. The drug may cause transient blurred vision; apply pressure over the nasolacrimal duct to minimize systemic absorption.
DARANIDE (dichlorphenamide) is a carbonic anhydrase inhibitor used for chronic open-angle glaucoma and secondary glaucoma. Monitor for metabolic acidosis, especially in patients with renal impairment. Can cause hypokalemia; check serum potassium periodically. Avoid concurrent use with high-dose salicylates due to risk of metabolic acidosis and salicylate toxicity. May cause drowsiness or confusion; caution in elderly. Not a first-line agent; reserved for patients intolerant or unresponsive to other therapies.
Instill one drop in the affected eye(s) three times daily, as directed.,Wash hands before and after use. Avoid touching the dropper tip to any surface.,If using other eye drops, wait at least 5 minutes between administrations.,Do not wear contact lenses during treatment; may discolor soft contact lenses.,Report eye pain, redness, vision changes, or signs of allergy (rash, itching).,May cause temporary blurred vision; do not drive or operate machinery until vision clears.,Store at room temperature, tightly closed, and protect from light.
Take exactly as prescribed, usually 3-4 times daily with food to reduce GI upset.,May cause tingling or numbness in fingers, toes, or mouth; this is common and usually harmless.,Drink plenty of fluids to prevent kidney stones; report painful urination or blood in urine.,Avoid aspirin or high-dose salicylates; check with doctor before taking any OTC pain relievers.,Regular eye exams and blood tests (potassium, bicarbonate) are necessary.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Tell your doctor if you have kidney disease, liver disease, or electrolyte imbalance.,Notify your doctor if you experience weakness, weight loss, confusion, or rapid breathing.
"Dorzolamide, a carbonic anhydrase inhibitor used for glaucoma, may theoretically inhibit the metabolism of cobicistat, a pharmacokinetic enhancer used in HIV therapy, by competing for hepatic CYP3A4 enzymes or altering renal clearance. This interaction could lead to increased cobicistat exposure, potentiating its adverse effects such as nephrotoxicity or gastrointestinal disturbances. However, clinically relevant interactions are unlikely due to dorzolamide's limited systemic absorption following ophthalmic administration."
"Chlorthalidone, a thiazide-like diuretic, and dorzolamide, a carbonic anhydrase inhibitor, both act to reduce bicarbonate reabsorption in the kidney, leading to enhanced electrolyte excretion, particularly potassium and bicarbonate. This synergistic effect can cause additive hypokalemia and metabolic acidosis, increasing the risk of cardiac arrhythmias and renal dysfunction. Concurrent use may also potentiate hypotensive effects due to volume depletion and vasodilation."
"Concurrent administration of dorzolamide, a carbonic anhydrase inhibitor, may reduce the urinary acidification necessary for methenamine's conversion to formaldehyde, the active antibacterial agent. This alkalinization of urine pH impairs the therapeutic efficacy of methenamine in treating urinary tract infections. Clinically, this can result in suboptimal bactericidal activity and potential treatment failure."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DORZOLAMIDE HYDROCHLORIDE vs DARANIDE, answered by our medical review team.
DORZOLAMIDE HYDROCHLORIDE is a Carbonic Anhydrase Inhibitor that works by Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.. DARANIDE is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DORZOLAMIDE HYDROCHLORIDE and DARANIDE depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DORZOLAMIDE HYDROCHLORIDE is: One drop of 2% solution in the affected eye(s) three times daily.. The standard adult dose of DARANIDE is: 50 mg orally once or twice daily; maximum 100 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DORZOLAMIDE HYDROCHLORIDE and DARANIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DORZOLAMIDE HYDROCHLORIDE is classified as Category C. Dorzolamide is a carbonic anhydrase inhibitor. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2.5 mg/kg/day (ra. DARANIDE is classified as Category C. Pregnancy Category C. First trimester: Possible association with congenital malformations (limited human data; animal studies show fetal toxicity). Second/third trimester: Risk of . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.